Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Operating Margin (2019 - 2025)

Historic Operating Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 120.3%.

  • BridgeBio Pharma's Operating Margin rose 68983700.0% to 120.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 172.39%, marking a year-over-year increase of 775900.0%. This contributed to the annual value of 267.22% for FY2024, which is 62615300.0% up from last year.
  • BridgeBio Pharma's Operating Margin amounted to 120.3% in Q3 2025, which was up 68983700.0% from 121.45% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Operating Margin ranged from a high of 19953.49% in Q4 2021 and a low of 38200.0% during Q3 2022
  • In the last 5 years, BridgeBio Pharma's Operating Margin had a median value of 6377.94% in 2021 and averaged 6756.95%.
  • The largest annual percentage gain for BridgeBio Pharma's Operating Margin in the last 5 years was 1244526700bps (2021), contrasted with its biggest fall of -388120600bps (2021).
  • Quarter analysis of 5 years shows BridgeBio Pharma's Operating Margin stood at 19953.49% in 2021, then tumbled by -135bps to 6910.8% in 2022, then tumbled by -47bps to 10167.11% in 2023, then skyrocketed by 62bps to 3842.69% in 2024, then skyrocketed by 97bps to 120.3% in 2025.
  • Its Operating Margin was 120.3% in Q3 2025, compared to 121.45% in Q2 2025 and 89.49% in Q1 2025.